Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Fetal Tissue, Stem Cells & Bioethics

The Continuing Promise of Non-Embryonic Stem Cells

The California based City of Hope, one of the country’s leading cancer research hospitals, recently sent out birthday greetings to the California Institute for Regenerative Medicine (CIRM), the nation’s leading funder — apart from the federal government – of stem cell research.

 

“On its 10th birthday, the California Institute for Regenerative Medicine celebrated 10 stem cell therapies that have been approved for clinical trials, including an HIV/AIDS trial at City of Hope,” the message read.

 

The birthday greeting contained an unintended irony, for while CIRM was approved by California voters a decade ago to give priority funding to human embryonic stem cell research, eight of the 10 approved clinical trials referenced by City of Hope were for research projects using adult and other non-embryonic stem cells.

 

The fact that 80% of the approved clinical trials based on research projects funded by CIRM are using non-embryonic stem cells is yet further evidence of a trend previously identified on this website: that ethically non-contentious adult and other non-embryonic stem cells are proving far more useful in actually leading to therapeutic benefits for patients than hESCs (human embryonic stem cells), and that this has been reflected in a sustained increase in funding by CIRM for such non-embryonic stem cell research over the years (here and here).

 

Moreover, research using adult and induced pluripotent stem cells (iPSCs) is providing promising and ethically non-contentious alternatives for treating the conditions in the two clinical trials using hESCs.

iPSC-simple

One of the hESC trials is for spinal cord injury (SCI).  Yet just last month, doctors announced that a man who had been paralyzed from the neck down was able to walk, with assistance, after being treated with his own adult stem cells.  (Dozens of other SCI patients have undergone a similar adult stem cell treatment with positive results; see also the research by CLI associate scholar Jean Peduzzi-Nelson.)

 

The other hESC clinical trial is for retinal degeneration, specifically age-related macular degeneration (AMD).

 

Here again, non-embryonic stem cells provide an ethically non-contentious alternative to hESCs.  Japanese researchers have already conducted an experiment to treat a woman with AMD using retinal tissue developed from her own iPSCs.

 

Researchers have also discovered adult stem cells in the retinal pigment epithelium (RPE), a cell layer that supports photoreceptors in the eye.  In other studies, researchers have used autologous RPE grafts to treat AMD patients, again with promising results.

 

As referenced before on this website, in 1999, when then-President Clinton’s National Bioethics Advisory Commission (NBAC) first endorsed federal funding for hESC research it nonetheless, in recognition of the ethical problems associated with it, made the pursuit of such research conditional.  Harvesting “left-over” IVF embryos for stem cells “is justifiable only if no less morally problematic alternatives are available for advancing the research (at pg. 53).”  In other words, given the ethical problems associated with it, hESCR should not be pursued if viable, ethically non-contentious alternatives to it exist.  At the time, the NBAC judged that such alternatives did not exist; however, that judgment was provisional and “is a matter that must be revisited continually as science advances.”

 

That eight of the 10 approved clinical trials based on CIRM-funded research projects are using non-embryonic stem cells is yet more evidence that those alternatives exist.  And given the research on AMD and SCI cited above, that 80 percent of approved, non-embryonic, clinical trials could be 100 percent.

 

Arguably, adult and other non-embryonic stem cell research should no longer be considered the “alternatives” for treating patients.

 

Gene Tarne is Senior Analyst for Charlotte Lozier Institute.

Latest Posts

March 1, 2024 Fact of Life: American Cars (and Their Drivers) Exhibit Decidedly More Pro-life than Pro-choice Views Fact of Life: American Cars (and Their Drivers) Exhibit Decidedly More Pro-life than Pro-choice Views February 29, 2024 Abortion Reporting: Nevada (2022) February 29, 2024 Abortion Reporting: Illinois (2022)

You Might Also Be Interested In

Lozier Institute Amicus Brief in Support of Ecuador Law Limiting Abortion

Lozier Institute Amicus Brief in Support of Ecuador Law Limiting Abortion

charlotte-lozier-institute Charlotte Lozier Institute
February 21, 2024
ClosePlease login
Public Comment: Lozier Institute on CDC’s Notice of Proposed Modifications to Assisted Reproductive Technology Program Reporting

Public Comment: Lozier Institute on CDC’s Notice of Proposed Modifications to Assisted Reproductive Technology Program Reporting

charlotte-lozier-institute Charlotte Lozier Institute
February 21, 2024
ClosePlease login
Stopping the Pain and Saving Lives:  Successful Treatments for Sickle Cell Disease

Stopping the Pain and Saving Lives: Successful Treatments for Sickle Cell Disease

February 5, 2024
ClosePlease login

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image